<?xml version="1.0" encoding="UTF-8"?>
<ref id="B140-pharmaceuticals-12-00157">
 <label>140.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Kuivanen</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Bespalov</surname>
    <given-names>M.M.</given-names>
   </name>
   <name>
    <surname>Nandania</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Ianevski</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Velagapudi</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>De Brabander</surname>
    <given-names>J.K.</given-names>
   </name>
   <name>
    <surname>Kainov</surname>
    <given-names>D.E.</given-names>
   </name>
   <name>
    <surname>Vapalahti</surname>
    <given-names>O.</given-names>
   </name>
  </person-group>
  <article-title>Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism</article-title>
  <source>Antivir. Res.</source>
  <year>2017</year>
  <volume>139</volume>
  <fpage>117</fpage>
  <lpage>128</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2016.12.022</pub-id>
  <pub-id pub-id-type="pmid">28049006</pub-id>
 </element-citation>
</ref>
